A5008892178- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Immune cells in cancer
- Heat shock proteins research
- Cancer Research and Treatments
- Carbohydrate Chemistry and Synthesis
- Enzyme Catalysis and Immobilization
- Glycosylation and Glycoproteins Research
- Monoclonal and Polyclonal Antibodies Research
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
- Mathematical Biology Tumor Growth
- Immune Cell Function and Interaction
- Enzyme Structure and Function
- Computational Drug Discovery Methods
- Alzheimer's disease research and treatments
- Cancer Cells and Metastasis
- Microbial Natural Products and Biosynthesis
- Colorectal Cancer Treatments and Studies
- Chemical Synthesis and Analysis
- Advanced Sensor and Energy Harvesting Materials
- Click Chemistry and Applications
- ATP Synthase and ATPases Research
- Protein purification and stability
East China Normal University
2024
University of Chinese Academy of Sciences
2023
Shenzhen Institutes of Advanced Technology
2023
Chinese Academy of Sciences
2023
China Southern Power Grid (China)
2023
Huazhong Agricultural University
2019-2020
Ministry of Agriculture and Rural Affairs
2019-2020
Ardelyx (United States)
2014-2017
Nanyang Technological University
2016
Memorial Sloan Kettering Cancer Center
2008-2012
Summary CRISPR /Cas systems provide bacteria and archaea with molecular immunity against invading phages foreign plasmids. The class 2 type VI effector Cas13a is an RNA ‐targeting that provides protection phages. Here we report the repurposing of /Cas13a to protect potato plants from a eukaryotic virus, Potato virus Y ( PVY ). Transgenic lines expressing Cas13a/sg (small guide ) constructs showed suppressed accumulation disease symptoms. levels viral resistance correlated expression...
ADVERTISEMENT RETURN TO ISSUEPREVArticleNEXTEnzyme-catalyzed aldol condensation for asymmetric synthesis of azasugars: synthesis, evaluation, and modeling glycosidase inhibitorsTetsuya Kajimoto, Kevin K. C. Liu, Richard L. Pederson, Ziyang Zhong, Yoshitaka Ichikawa, John A. Porco Jr., Chi Huey WongCite this: J. Am. Chem. Soc. 1991, 113, 16, 6187–6196Publication Date (Print):July 1, 1991Publication History Published online1 May 2002Published inissue 1 July...
ADVERTISEMENT RETURN TO ISSUEPREVArticleNEXTUse of dihydroxyacetone phosphate-dependent aldolases in the synthesis deoxy aza sugarsKevin K. C. Liu, Tetsuya Kajimoto, Lihren Chen, Ziyang Zhong, Yoshitaka Ichikawa, and Chi Huey WongCite this: J. Org. Chem. 1991, 56, 22, 6280–6289Publication Date (Print):October 1, 1991Publication History Published online1 May 2002Published inissue 1 October 1991https://pubs.acs.org/doi/10.1021/jo00022a013https://doi.org/10.1021/jo00022a013research-articleACS...
We describe the development and characterization of a mouse human epithelial cell monolayer platform small large intestines, with broad range potential applications including discovery minimally systemic drug candidates. Culture conditions for each intestinal segment were optimized by correlating global gene expression corresponding tissue segment. The monolayers polarized, formed tight junctions, contained diversity lineages. Ion transport phenotypes from proximal distal colon intestine...
In CKD, phosphate retention arising from diminished GFR is a key early step in pathologic cascade leading to hyperthyroidism, metabolic bone disease, vascular calcification, and cardiovascular mortality. Tenapanor, minimally systemically available inhibitor of the intestinal sodium-hydrogen exchanger 3, being evaluated clinical trials for its potential (1) lower gastrointestinal sodium absorption, (2) improve fluid overload-related symptoms, such as hypertension proteinuria, patients with...
The clinical success of the immune checkpoint inhibitor (ICI) targeting programmed cell death protein 1 (PD-1) has revolutionized cancer treatment. However, full potential PD-1 blockade therapy remains unrealized, as response rates are still low across many types. Interleukin-2 (IL-2)-based immunotherapies hold promise, they can stimulate robust T expansion and enhance effector function - activities that could synergize potently with blockade. Yet, IL-2 therapies also carry a significant...
We conducted a phase I dose-escalation study to define the maximum tolerated dose (MTD), pharmacokinetics (PK), and pharmacodynamics of alvespimycin (17-DMAG), heat shock protein 90 (Hsp90) inhibitor, given in combination with trastuzumab.Patients were treated trastuzumab followed by intravenous on weekly schedule. Hsp90 client proteins measured at baseline serially peripheral blood lymphocytes (PBL) during cycle 1. Patients advanced solid tumors progressing standard therapy...
ADVERTISEMENT RETURN TO ISSUEPREVArticleNEXTEngineering subtilisin for reaction in dimethylformamideZiyang Zhong, Jennifer L. C. Liu, Lois M. Dinterman, Malcolm A. J. Finkelman, W. Thomas Mueller, Michele Rollence, Marc Whitlow, and Chi Huey WongCite this: Am. Chem. Soc. 1991, 113, 2, 683–684Publication Date (Print):January 1, 1991Publication History Published online1 May 2002Published inissue 1 January...
The epothilones represent a promising class of natural product-based antitumor drug candidates. Although these compounds operate through microtubule stabilization mechanism similar to that taxol, the offer major potential therapeutic advantage in they retain their activity against multidrug-resistant cell lines. We have been systematically synthesizing and evaluating synthetic epothilone congeners are not accessible modification product itself. report herein results biological investigations...
ADVERTISEMENT RETURN TO ISSUEPREVArticleNEXTEnzymes as synthetic catalysts: mechanistic and active-site considerations of natural modified chymotrypsinJ. Blair West, William J. Hennen, James L. Lalonde, Jeffrey A. Bibbs, Ziyang Zhong, Edgar F. Meyer Jr., Chi Huey WongCite this: Am. Chem. Soc. 1990, 112, 13, 5313–5320Publication Date (Print):June 1, 1990Publication History Published online1 May 2002Published inissue 1 June...
A major histopathological feature of Alzheimer's disease is deposits a approximately 4-kDa beta-amyloid peptide derived by proteolytic processing from precursor, the precursor protein (beta-APP). Proteolytic cleavage beta-APP within domain permits secretion amino-terminal portion while concomitantly producing membrane bound 9-kDa carboxyl-terminal fragment. We have characterized site for amino acid sequence analysis product produced recombinant and native expression systems. Recombinant was...
Efficient purification of ethylene (C2H4) from acetylene/ethylene/ethane (C2H2/C2H4/C2H6) mixture is crucial but challenging. For this purpose, an ideal process supposed that the adsorbent has specific adsorption regions for guest...
Abstract Despite the success of immune checkpoint inhibitors (ICIs) in treating solid tumors, lots patients remain unresponsive to this therapy. Microwave ablation (MWA) stimulates systemic adaptive immunity against tumor cells by releasing antigens. Additionally, IL-21 has demonstrated importance stimulating T-cell effector function. The combination these three therapies—MWA, IL-21, and anti-PD-1 monoclonal antibodies (mAbs)—has yet be explored context cancer treatment. In study, we impact...
Antibody-Drug Conjugates (ADCs) are targeted cancer therapies delivering cytotoxic agents selectively to cells. Despite clinical success across various malignancies, resistance ADC therapy limits long-term efficacy. A key mechanism is inducing immunogenic cell death (ICD), releasing damage-associated molecular patterns (DAMPs) and tumor antigens stimulate an immune response. This provides a rationale for combining ADCs with immunotherapies overcome improve survival rates.AWT020 novel fusion...
e14500 Background: Whileimmune checkpoint inhibitors have become the standard of care for multiple cancer types, resistance to anti-PD-(L)1 therapies remains a significant unmet medical need. AWT020 is bifunctional fusion protein comprised an anti-PD-1 antibody and potency optimized IL-2. Preclinical studies using mouse surrogate demonstrated superior antitumor activity compared either anti-mPD-1 alone or its combination with IL-2 in sensitive resistant models. These findings suggest that...
Inhibition of the protein chaperone Hsp90 is a promising new approach to cancer therapy. We describe preparation potent non-benzoquinone ansamycins. One these analogues, generated by feeding 3-amino-5-chlorobenzoic acid genetically engineered strain Streptomyces hygroscopicus, shows high accumulation and long residence time in tumor tissue, well-tolerated upon intravenous dosing, highly efficacious COLO205 mouse xenograft model.
T cell-stimulating cytokines and immune checkpoint inhibitors (ICI) are an ideal combination for increasing response rates of cancer immunotherapy. However, the results clinical trials have not been satisfying. It is important to understand mechanism synergy between these two therapeutic modalities. Here, through integrated analysis multiple single-cell RNA sequencing (scRNA-seq) datasets human tumor-infiltrating cells, we demonstrate that IL21 produced by tumor-associated follicular helper...
ADVERTISEMENT RETURN TO ISSUEPREVArticleNEXTActive-site-directed modification of subtilisinZiyang Zhong, Jeffrey A. Bibbs, Wei Yuan, and Chi Huey WongCite this: J. Am. Chem. Soc. 1991, 113, 6, 2259–2263Publication Date (Print):March 1, 1991Publication History Published online1 May 2002Published inissue 1 March 1991https://pubs.acs.org/doi/10.1021/ja00006a052https://doi.org/10.1021/ja00006a052research-articleACS PublicationsRequest reuse permissionsArticle Views476Altmetric-Citations27LEARN...